0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

AN EVALUATION OF THE CLINICAL TOXICITY OF SULFANILAMIDE AND SULFAPYRIDINE

W. HURST BROWN, D.M., M.R.C.P.; WILLIAM B. THORNTON, M.D.; J. STUART WILSON
JAMA. 1940;114(17):1605-1611. doi:10.1001/jama.1940.02810170001001.
Text Size: A A A
Published online

The enthusiasm which attended the successful use of sulfanilamide in a remarkably wide range of infections has now been transferred to sulfapyridine. The undoubted ability of this drug to combat pneumococcic infections has naturally led to its widespread adoption in the treatment of pneumonia; but, because it is apparently as potent as sulfanilamide in other types of infection, there is a growing tendency to employ the new in place of the old and proved compound. Before this trend becomes too pronounced it seems timely to inquire into the relative toxicity of the two drugs. This is the more necessary when it is recalled that clinicians have not yet reached agreement as to the blood concentrations of sulfapyridine that are adequate to control pneumonia of pneumococcic origin. Until matters of such fundamental importance are settled, expediency should be tempered by caution.

In the present communication an attempt has been made to

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();